GITR contributes to the systemic adjuvanticity of the Escherichia coli heat‐labile enterotoxin
暂无分享,去创建一个
R. Rappuoli | C. Riccardi | J. Merino | Jovanna González | G. Del Giudice | R. Merino | M. Iglesias | E. Tamayo | J. Postigo | Inés Santiuste | M. Fernández-Rey | Jovanna González
[1] R. Rappuoli,et al. Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin , 2009, PloS one.
[2] R. Rappuoli,et al. Involvement of the intrinsic and extrinsic cell‐death pathways in the induction of apoptosis of mature lymphocytes by the Escherichia coli heat‐labile enterotoxin , 2009, European journal of immunology.
[3] D. Vanrompay,et al. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. , 2006, Veterinary research.
[4] R. Rappuoli,et al. The Escherichia coli heat‐labile enterotoxin induces apoptosis of immature lymphocytes in vivo via a glucocorticoid‐dependent pathway , 2005, European journal of immunology.
[5] C. Riccardi,et al. The Glucocorticoid-Induced Tumor Necrosis Factor Receptor-Related Gene Modulates the Response to Candida albicans Infection , 2005, Infection and Immunity.
[6] C. Czerkinsky,et al. In Vivo Adjuvant-Induced Mobilization and Maturation of Gut Dendritic Cells after Oral Administration of Cholera Toxin1 , 2004, The Journal of Immunology.
[7] C. Riccardi,et al. Frontline: GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations , 2004, European journal of immunology.
[8] Robert T. Chen,et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. , 2004, The New England journal of medicine.
[9] R. Rappuoli,et al. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines , 2003, Expert review of vaccines.
[10] B. Kwon,et al. Soluble glucocorticoid‐induced tumor necrosis factor receptor (sGITR) increased MMP‐9 activity in murine macrophage , 2003, Journal of cellular biochemistry.
[11] P. Pandolfi,et al. Role of GITR in activation response of T lymphocytes. , 2002, Blood.
[12] J. Shimizu,et al. Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance , 2002, Nature Immunology.
[13] T. Hirst,et al. Protective Mucosal Immunity to Ocular Herpes Simplex Virus Type 1 Infection in Mice by Using Escherichia coli Heat-Labile Enterotoxin B Subunit as an Adjuvant , 2001, Journal of Virology.
[14] J. Mcghee,et al. Cutting Edge: The Mucosal Adjuvant Cholera Toxin Redirects Vaccine Proteins into Olfactory Tissues , 2000, The Journal of Immunology.
[15] D. O'hagan,et al. Genetically detoxified mutants of heat‐labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T‐cell responses against HIV‐1 gag‐p55 , 2000, Immunology.
[16] Antonio Lanzavecchia,et al. Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming , 2000, European journal of immunology.
[17] G. Dougan,et al. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. , 1999, Journal of immunology.
[18] G. Dougan,et al. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. , 1999, Immunology today.
[19] G. Dougan,et al. Genetically Detoxified Mutants of Heat-Labile Toxin from Escherichia coli Are Able To Act as Oral Adjuvants , 1999, Infection and Immunity.
[20] Y. Takeda,et al. Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant. , 1999, Journal of immunology.
[21] A. Lanzavecchia,et al. T lymphocyte costimulation mediated by reorganization of membrane microdomains. , 1999, Science.
[22] G. Dougan,et al. Mucosal Adjuvanticity and Immunogenicity of LTR72, a Novel Mutant of Escherichia coli Heat-labile Enterotoxin with Partial Knockout of ADP-ribosyltransferase Activity , 1998, The Journal of experimental medicine.
[23] Kenneth G. C. Smith,et al. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes , 1998, The EMBO journal.
[24] C. Elson,et al. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression. , 1997, Journal of immunology.
[25] C. Riccardi,et al. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[26] D. Longo,et al. Increased proliferation, cytotoxicity, and gene expression after stimulation of human peripheral blood T lymphocytes through a surface ganglioside (GD3) , 1994, Journal of immunology.
[27] T. Nagamine,et al. Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB. , 1989, Vaccine.
[28] D. E. Parks,et al. Modulation of the induction and circumvention of immunological tolerance to human gamma-globulin by interleukin 1. , 1987, Journal of immunology.
[29] T. Cheng,et al. Flow cytometry-based cell cycle measurement of mouse hematopoietic stem and progenitor cells. , 2008, Methods in molecular biology.
[30] M. G. Ferrari,et al. Mucosal adjuvants. , 2005, Current pharmaceutical design.